• Laboratoires Pierre Fabre Dermatologie, of Castres, France, a subsidiary of Laboratoires Pierre Fabre, and Maruho Co. Ltd., of Osaka, Japan, inked a licensing deal to develop and market in Japan an oral formulation of a pediatric beta-blocker for the treatment of infantile hemangioma requiring a systemic therapy.